Menu Search
Equities

Haemonetics Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HAZ:FRA

Haemonetics Corp

Actions
  • Price (EUR)55.00
  • Today's Change0.50 / 0.92%
  • Shares traded13.00
  • 1 Year change-10.57%
  • Beta0.3105
Data delayed at least 15 minutes, as of Mar 05 2026 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Haemonetics Corp grew revenues 3.95% from 1.31bn to 1.36bn while net income improved 42.64% from 117.56m to 167.68m.
Gross margin59.32%
Net profit margin13.31%
Operating margin19.05%
Return on assets6.99%
Return on equity19.30%
Return on investment8.30%
More ▼

Cash flow in USDView more

In 2025, Haemonetics Corp increased its cash reserves by 71.57%, or 127.96m. The company earned 181.73m from its operations for a Cash Flow Margin of 13.35%. In addition the company generated 108.82m cash from financing while 161.90m was spent on investing.
Cash flow per share5.99
Price/Cash flow per share10.43
Book value per share19.46
Tangible book value per share-2.46
More ▼

Balance sheet in USDView more

Haemonetics Corp has a Debt to Total Capital ratio of 57.33%, a lower figure than the previous year's 134.50%.
Current ratio1.75
Quick ratio1.15
Total debt/total equity1.34
Total debt/total capital0.5733
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)17.48
EPS (TTM) vs
TTM 1 year ago		43.23
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.